Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 424  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
01/22/2015 > 211 patent applications in 113 patent subcategories.

20150023868 - Hif inhibitors and use thereof: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.... Agent: The General Hospital Corporation

20150023867 - Methods of myocardial perfusion imaging: The present invention provides a method of myocardial perfusion imaging using reduced doses of (1-{9-[(4S,2R,3R,5R)3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide.... Agent: Gilead Sciences, Inc.

20150023869 - Radioactive compositions and methods for their therapeutic use: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.... Agent: Isotherapeutics Group LLC

20150023870 - Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases: Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target... Agent: Ibc Pharmaceuticals, Inc.

20150023871 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20150023873 - Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging: The invention provides, in some embodiments, methods relating to assessing increased risk of developing atrial fibrillation (AF), and/or the likelihood of responding to particular AF therapies using imaging agents comprising an MMP inhibitor linked to an imaging moiety. The invention further provides methods for evaluating the presence of the risk... Agent: Yale University

20150023874 - Folate receptor alpha binding ligands: The invention described herein pertains to targeted drug delivery conjugates comprising folate receptor α (FR-α) selective binding ligands and methods for diagnosing, monitoring, and eliminating pathological cells that express FR-α.... Agent:

20150023872 - Homing agents: The present disclosure provides peptide constructs for diagnostic imaging and therapeutic applications, using pegylated peptides which exhibit specific binding for a target molecule of interest, such as a biomarker of a disease or disorder.... Agent:

20150023876 - Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders: A method of diagnosing a CD206 expressing cell-related disorder by administering a pharmaceutical composition to a subject, the composition including a carrier molecule having a detectable moiety attached thereto. The carrier molecule has a dextran backbone, and at least one receptor substrate conjugated, directly or indirectly, to the dextran backbone,... Agent:

20150023875 - System for targeted delivery of therapeutic agents: The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles.... Agent: The Brigham And Women's Hospital, Inc.

20150023877 - Methods of parkinsons disease diagnosis and monitoring treatment: Embodiments of the present disclosure provide for methods of using labeled probes, methods of diagnosing Parkinson's disease and related biological events, methods of using labeled probes for monitoring and/or assessing Parkinson's disease treatment, methods of using labeled probes for diagnosing, monitoring, and/or assessing diseases with aberrant melanin-expression, and the like.... Agent:

20150023878 - Novel aspartylamide inhibitors of excitatory amino acid transporters: or a salt, ester or prodrug thereof, wherein X is a halogen, such as fluorine, or a radionuclide, such as fluorine-18. The compounds and methods described herein can be used for the treatment of, e.g., neurodegenerative disorders (e.g., amyotrophic lateral sclerosis), ischemia, spinal cord injury, and traumatic brain injury in... Agent:

20150023879 - Diagnostic chewing gum for pathogens: The document proposes a diagnostic chewing gum for identifying the presence of pathogens detectable via the mouth, in particular residing in nasal, oropharyngeal, laryngeal, oesophageal, ocular and/or pulmonal tissue of a user, comprising a base material or particles (3) embedded and/or attached to said base material; an element (1, 5-7),... Agent: Julius-maximilians-universitaet Wuerzburg

20150023882 - Aqueous method for making magnetic iron oxide nanoparticles: The invention discloses an aqueous method of making polymer coated superparamagnetic nanoparticles. Nanoparticles made by the method are included in the invention.... Agent: University Of Central Florida Research Foundation, Inc.

20150023880 - Preparation of a lipid blend and a phospholipid suspension containing the lipid blend: The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.... Agent: Lantheus Medical Imaging, Inc.

20150023881 - Contrast agent for combined photoacoustic and ultrasound imaging: A microbubble is used as a multi-modality contrast agent for photoacoustic imaging and ultrasound imaging. A method of preparing improved microbubbles that are used as a multi-modality contrast agent for photoacoustic imaging and ultrasound imaging is provided. The microbubble includes a dye-colored lipid shell; and a filling gas filling the... Agent: Samsung Medison Co., Ltd.

20150023883 - Antiperspirant spray devices and compositions: A hand held spray device is disclosed. The spray device has a body with a reservoir, an actuator having an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir, and a propellant and antiperspirant composition stored in the reservoir. The propellant has a... Agent:

20150023884 - Antiperspirant spray devices and compositions: A hand held spray device is disclosed. The spray device has a body with a reservoir, an actuator having an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir, and a propellant and antiperspirant composition stored in the reservoir. The propellant has a... Agent:

20150023885 - Antiperspirant spray devices and compositions: A hand held spray device is disclosed. The spray device has a body with a reservoir to house a total fill of material, an actuator having an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir, and a propellant and antiperspirant composition stored... Agent:

20150023886 - Antiperspirant spray devices and compositions: A hand held spray device is disclosed. The spray device has a body with a reservoir to house a total fill of material, an actuator having an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir, and a propellant and antiperspirant composition stored... Agent:

20150023887 - Antiperspirant spray devices and compositions: A hand held spray device is disclosed. The spray device includes a body with a reservoir, an actuator with an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir and a propellant and antiperspirant composition stored in the reservoir. The propellant has a... Agent:

20150023888 - Method of using dihydroergotamine for pre-emptive treatment of migraine: The invention is drawn to a novel, early interventional use of a pharmaceutical composition wherein administration of said pharmaceutical composition pre-empts the onset of migraine headaches, preferably anytime in the migraine cycle prior to pain onset. The pharmaceutical composition preferably is administered via inhalation in order to provide therapy to... Agent: Map Pharmaceuticals, Inc.

20150023889 - Fluoride-responsive riboswitchs, fluoride transporters, and methods of use: Disclosed are compounds, compositions, and methods relating to fluoride aptamers, fluoride-responsive riboswitches, fluoride-regulated expression constructs, fluoride transporters, nucleic acids encoding fluoride transporters, expression constructs encoding fluoride transporters, and cells containing or including any combination of these.... Agent:

20150023890 - High fluoride ion oral care composition and method for maintaining anticaries activity: An oral care composition and method of maintaining anticaries activity of fluoride ion in an oral care composition are described. An oral care composition comprises a fluoride ion source sufficient to maintain a high fluoride content in the composition, an effective amount of a desensitizing agent and water. A method... Agent:

20150023891 - Natural anti-bacterial toothpaste composition containing improvement in tooth pain, antibacterial mouth and nerve stability: The present invention relates to natural anti-bacterial toothpaste composition containing improvement in tooth pain, antibacterial mouth and nerve stability and particularly, it enables to contribute to improvement in tooth pain, antibacterial mouth and nerve stability, which represent effects of Na2SiO3-10H20 and oriental medicine, due to more than 63˜75% of SiO3,... Agent:

20150023892 - Mouth wash compositions for denture adhesive removal: An antiseptic, polymer-lipid or emulsification agents-based aqueous composition can be used for intraoral removal of denture adhesive residuals. More particularly, the present invention relates to employing a polymer-lipid based or a mixture of polymer-lipids and emulsification agents or a mixture of emulsification agents and Co-emulsification agents for convenient and effective... Agent:

20150023894 - Method for producing microcapsules with a sun protection effect: A method for producing microcapsules with a sun protection effect includes mixing tetraethoxysilane (TEOS), ethanol, and water and uniformly vibrating the mixture of TEOS, ethanol, and water. The TEOS, ethanol, and water have an appropriate ratio therebetween. Nitric acid is used to adjust the mixture of TEOS, ethanol, and water... Agent:

20150023893 - Method of improving the appearance of aging skin: A method of improving the appearance of aging skin that includes applying an effective amount of artichoke leaf extract and vitamin B3 compound in combination to a target area of skin that exhibits a sign of aging skin, and compositions that include an effective amount of artichoke leaf extract and... Agent:

20150023896 - System and method of complimentary day/night children's skin cream compositions: A new skin care system includes day and night skin cream compositions comprising nutrients and antioxidants for use by children between six months and eighteen years of age. The day skin cream composition provides protection from UV radiation and the night skin cream composition contains no sun protection ingredients and... Agent:

20150023895 - Uv compositions having low active concentrations and high in vivo spf: At least one of R1 or R2 is a C1-C8 alkyoxy radical, and one of R1 or R2 is a straight or branched chain C1-C30 alkoxy radical or any non-alkoxy radical, or hydrogen; and R3 is a straight or branched chain C1-C30 alkyl. Further, the UV composition comprises from about... Agent:

20150023897 - Method of protecting skin from oxidative stress: A method of protecting skin from an environmental stressor that includes identifying a target skin portion where protection from environmental stress is desired and topically applying a suitable skin care composition thereto. The skin composition may include a safe and effective amount of a vitamin B3 compound, a safe and... Agent:

20150023898 - Composite particles, method for production thereof, and use thereof: The present invention relates to composite particles comprising a carrier material as well as at least one pearlescent pigment, wherein the carrier material and the at least one pearlescent pigment are bonded to one another without an adhesive agent. In addition, the invention relates to a method for producing these... Agent:

20150023899 - Pigment mixture: The present invention relates to a pigment mixture based on spherical particles having a defined particle-size distribution, and to the use thereof in paints, coatings, printing inks, security printing inks, plastics, ceramic materials, glasses, in cosmetic formulations, as tracer, as filler and for the preparation of pigment preparations and dry... Agent: Merck Patent Gmbh

20150023900 - Amino acid-modified siloxanes, process for preparing them and application: A process for preparing amino acid-modified siloxanes that can be carried out under mild conditions is provided as well as organically modified silicones for care formulations for skin, hair and textiles that are toxicologically unobjectionable.... Agent: Evonik Industries Ag

20150023901 - Hair treatment agents containing 4-morpholino-methyl-substituted silicone(s) and thickening agent(s): Cosmetic compositions include in a cosmetically acceptable medium at least one thickening agent and at least one 4-morpholino-methyl-substituted silicone of formula (V), in which A represents structural unit (I), (II) or (III) or an O-bound oligomeric or polymeric radical including structural units of formulae (I), (II) or (III) or half... Agent: Henkel Ag & Co. Kgaa

20150023902 - Cosmetic use of an extract of balanites almonds to improve hair strength: The invention concerns the use of a cosmetic compound to improve hair strength, said cosmetic compound comprising as an active ingredient an extract of Balanites almonds.... Agent: Pierre Fabre Dermo-cosmetique

20150023903 - Aldehyde gas deodorant and method for producing same: A method for producing an aldehyde gas deodorant, the method comprises the steps of: preparing a deodorizing composition containing a dihydrazide compound, a water-containing inorganic powder, and water; and heating the deodorizing composition at a temperature of from 45° C. to 90° C. so that water remains in an amount... Agent: Toagosei Co., Ltd

20150023904 - New application of pvp-i: The present invention relates to an application of povidone iodine (PVP-I) in the preparation of a medicine treating premature ejaculation, wherein the medicine is the compound consisting of PVP-I and any other biologically compatible carrier, such as PVP-I disinfectant or Andoful PVP-I disinfectant. The beneficial effect is: by experiment, PVP-I... Agent:

20150023905 - Synthetic mechanical hemostatic composition, method of making and use thereof: A biocompatible, polymeric composition is disclosed. The composition comprises a base polymer comprising (i) a prepolymer comprising para-dioxanone (PDO) and trimethylene carbonate (TMC); and (ii) an end-graft polymer chain comprising a polylactone. Also disclosed are a method for treating bleeding from bone or bony structures using the composition, a method... Agent: Poly-med, Inc.

20150023906 - Formulation comprising a particulate calcium silicate and clonostachys rosea for treating plants: A powder plant treatment formulation for application to plants by insect vectoring includes: a plant treatment agent; a stabilizing agent bonded to the plant treatment agent for stabilizing the plant treatment agent; a moisture absorption agent for absorbing moisture from the formulation; an attracting agent for attracting the formulation to... Agent: Bee Vectoring Technology Inc.

20150023907 - Reactivation of hiv-1 gene expression to treat persistent hiv infection: The present invention provides new methods of treatment of lentiviral infections, more particularly to treat latent retroviral HIV infections, present in cells of the infected subject, based on the re-activation of said viruses. The invention uses a combination therapy using several agents that result in strong re-activation of the latent... Agent:

20150023912 - Combinations of albumin-based drug delivery systems: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.... Agent:

20150023911 - Device-based methods for localized delivery of cell-free carriers with stress-induced cellular factors: The present invention relates to an in vitro or ex vivo method of preparing a cell-free composition, said method comprising or consisting of (a) subjecting cells to stress; and (b) collecting factors produced, preferably secreted by said cells when subjected to said stress, thereby obtaining said cell-free composition; wherein said... Agent: Technische Universitaet Muenchen-klimikum Rechts Der Isar

20150023910 - Granulysin in immunotherapy: Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a... Agent:

20150023909 - Lymph node-targeting nanoparticles: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1α, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin... Agent:

20150023908 - Skin cream: The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising exosomes and cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of making and using such compositions and kits comprising the skin cream therein.... Agent:

20150023916 - Antiviral drugs for treatment of arenavirus infection: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by... Agent: Siga Technologies Inc.

20150023913 - Hepatitis c virus inhibitors: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.... Agent:

20150023917 - Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases: The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis B and Hepatitis D virus infections.... Agent: Novartis Ag

20150023915 - Treatment for melanoma: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.... Agent: The Board Of Regents Of The University Of Texas System

20150023914 - Use of tellurium compounds for the treatment actinic keratosis: Methods for treating skin conditions such as basal cell carcinoma and/or actinic keratosis are provided, which are effected by administering a pharmaceutically effective amount of a tellurium-containing compound. A pharmaceutical composition for treatment of skin conditions such as basal cell carcinoma and/or actinic keratosis is also provided.... Agent: Biomas Ltd.

20150023919 - Induction of tolerance in lung allograft transplantation: The present disclosure relates to methods of inducing tolerance to lung allograft transplantation. These methods comprise increasing nitric oxide, increasing suppressor CD8+ T cells and/or suppressing deleterious CD8+ and CD4+ T cells.... Agent:

20150023918 - Long acting proteins and peptides and methods of making and using the same: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via... Agent: Bolder Biotechnology, Inc.

20150023920 - Novel compositions and methods for preventing or treating cancer metastasis: The invention includes a method of preventing or treating metastasis in a subject diagnosed with cancer, the method comprising determining whether at least one gene encoding one or more proteins is upregulated in a cancer tissue sample from the subject as compared to the level of expression of the at... Agent: Drexel University

20150023921 - Hepatitis c antiviral compositions and methods: The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.... Agent: Biotron Limited

20150023922 - Methods for promoting neuronal development and/or health: The present disclosure relates to methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising a neurologic component, wherein the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include lactoferrin, zine sulfate, one... Agent:

20150023923 - Methods for promoting neuronal development and/or health: The present disclosure relates to methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising docosahexaenoic acid and alpha-lipoic acid. The nutritional composition may further include lactoferrin, a prebiotic, a probiotic, and mixtures thereof. Additionally the present disclosure provides methods for accelerating the development of... Agent:

20150023924 - Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues: The invention relates to adeno-associated virus (AAV) serotype AAV-Rh74 and related AAV vectors, and AAV-Rh74 and related AAV vector mediated gene transfer methods and uses. In particular, AAV-Rh74 and related AAV vectors target polynucleotides to cells, tissues or organs for expression (transcription) of genes encoding therapeutic proteins and peptides, and... Agent:

20150023932 - Engineered peptide (ep)-directed protein intercellular delivery system and uses thereof: The present invention provides an intercellular protein delivery system comprising an engineered peptide (EP), composed of secretion part (SP) and nuclear translocation part (NTP), a functional or therapeutic protein (FP), cells that express the fusion proteins and cells that accept the fusion proteins. The system can be used in vivo... Agent:

20150023934 - Generation of epithelial cells and organ tissue in vivo by reprogramming and uses thereof: The present invention encompasses methods for reprogramming fibroblast cells in culture, which are able to generate generic epithelial cells therefrom.... Agent:

20150023933 - Materials and methods relating to packaging cell lines: Lentiviral packaging cells and methods for producing the same are provided herein. Specifically, lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are provided. Methods for producing lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are described.... Agent: Ucl Business PLC

20150023935 - Reprogramming of aged adult stem cells: A method of reprogramming aged human or animal adult stem cells (AASC), comprising the steps of (a) collecting young adult stem cells (YASC) from the blood of a donor wherein the donor is less than 40 years old; (b) dissolving at least a portion of membranes of said YASC to... Agent:

20150023925 - Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition: The present invention relates to conjugated linoleic acid (CLA)-producing strains of probiotic bacteria. In particular, the present invention relates to a selection of bacterial strains belonging to the genus Bifidobacterium which were selected for their ability to produce conjugated linoleic acid (CLA) from linoleic acid (LA). Furthermore, the present invention... Agent:

20150023936 - Strain of lactobacillus acidophilus having analgesic properties in the gastrointestinal system: The invention proposes the use of at least one strain of Lactobacillus acidophilus to prepare a support administered to humans or animals with an analgesic purpose in the gastrointestinal system.... Agent:

20150023930 - Aminoquinoline derivatives and uses thereof: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine... Agent: The Mclean Hospital Corporation

20150023927 - Conversion of somatic cells into functional spinal motor neurons, and methods and uses thereof: The present invention provides methods of transdifferentiation of somatic cells, for example, directly converting a somatic cell of a first cell type, e.g., a fibroblast into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for converting a somatic... Agent: President And Fellows Of Harvard College

20150023931 - Methods of using regenerative cells in the treatment of musculoskeletal disorders: Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed... Agent:

20150023929 - Oral unit dosage forms and uses of same for the treatment of gaucher disease: A method of treating Gaucher's disease in a subject in need thereof is provided. The method comprising orally administering to the subject a therapeutically effective amount of recombinant glucocerecbrosidase (GCD) comprised in plant cells, wherein said therapeutically effective amount of GCD corresponds to 1-1920 units/Kg/14 days, thereby treating Gaucher's disease.... Agent: Protalix Ltd.

20150023928 - Stem cell preparations and methods of use: The present invention relates to a method of preparing cells and in particular to a method of preparing breastmilk stem cells (BSCs) by isolation from breastmilk and subsequent culture. The invention further relates to BSCs prepared by the methods of the invention and to methods and uses thereof. In one... Agent: Medela Holding Ag

20150023926 - Treatment of radiation injury using amnion derived adherent cells: Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of and compositions comprising, such cells.... Agent: Anthrogenesis Corporation

20150023939 - Apparatus and method for separating and concentrating fluids containing multiple components: An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample.... Agent:

20150023937 - Histone deacetylase (hdac) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacy: Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals... Agent:

20150023938 - Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens: Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence... Agent: Fred Hutchinson Cancer Research Center

20150023941 - Compositions comprising sugar-cysteine products: The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.... Agent:

20150023940 - Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme q10): Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.... Agent: Berg Pharma LLC

20150023944 - Method of treating and diagnosing parkinson's disease and related dysautonomic disorders: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease... Agent:

20150023942 - Compositions and methods for promoting neuronal outgrowth: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.... Agent:

20150023943 - Ref nuclease for site-specific ref-mediated dna cleavage: Purified Ref polypeptides with increased nuclease site-specific targeting activity, recombinant nucleic acids and cells for expression of such Ref polypeptides, and methods for using the Ref polypeptides in combination with RecA protein and variants thereof to effect targeted nuclease cleavage of a DNA duplex are disclosed.... Agent:

20150023945 - Lysozymes: The present invention is directed to lysozyme variants and nucleotide sequences encoding same. The lysozyme variants have antimicrobial and/or lysozyme activity and comprise an alteration of an amino acid sequence at one or more positions. The present invention is also directed to methods for producing and of using the Opisthocomus... Agent:

20150023946 - Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii: The present invention relates to pharmaceutical preparations comprising Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the treatment... Agent: Csl Behring Gmbh

20150023947 - Medicinal products for the treatment of blood coagulation disorders: A virally safe, thrombin-free factor-XIa concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation.... Agent:

20150023948 - Formulation for treatment of irritable bowel disease: The present invention relates to an effective formulation for the treatment or the prevention of irritable bowel syndrome, a method for treating irritable bowel syndrome, and processes for preparing such formulations.... Agent:

20150023950 - 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system: The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases... Agent:

20150023949 - Compositions and methods for diagnosis and treatment of pervasive developmental disorder: Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.... Agent:

20150023952 - Anti-addl monoclonal antibody and uses thereof: The present invention relates to antibodies that bind amyloid β-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to... Agent:

20150023951 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20150023953 - Method of treating cancer: Methods are provided for treating cancer in a patient in need thereof with a HER2 inhibitor, where such patients have certain polymorphisms in VEGFA, VEGFR or IGF1R.... Agent:

20150023954 - Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition: Methodologies and technologies for potentiating antibody-based cancer treatments by increasing complement-mediated cell cytotoxicity are disclosed. Further provided are methodologies and technologies for overcoming ineffective treatments correlated with and/or caused by sub-lytic levels of complement-activating monoclonal antibodies (“mAb”) against cancer antigens or cancer antigens with low tumor cell density. While detectable... Agent:

20150023955 - Treatment and diagnosis of melanoma: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.... Agent: The Rockefeller University

20150023959 - Chimeric factor viii polypeptides and uses thereof: The present invention provides a VWF fragment comprising the D′ domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a... Agent: Biogen Idec Ma Inc.

20150023960 - Compositions and methods of use for treating metabolic disorders: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.... Agent:

20150023958 - Fusion polypeptide inhibiting vegf-c, vegf-d and/or angiopoietin-2, and use thereof: A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof.... Agent:

20150023956 - Methods and compositions for increasing enzyme activity in the cns: Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibodies provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in mucopolysaccharidosis III (MPS-III). The fusion antibodies provided... Agent: Armagen Technologies, Inc.

20150023961 - Methods of modulating immunological responses by administering truncated baff receptors: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.... Agent: Biogen Idec Ma Inc.

20150023957 - Saa domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.... Agent: The Feinstein Institute For Medical Research

20150023962 - Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other... Agent:

20150023964 - Fcgammariib-specific antibodies and methods of use thereof: The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent... Agent: Macrogenics, Inc.

20150023963 - Method for the production of variable domains: The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable... Agent: Ablynx N.v.

20150023967 - Binding molecules for bcma and cd3: The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster3 of BCMA, and the second binding domain is capable of binding to the Tcell CD3 receptor complex.... Agent:

20150023966 - Combination therapies using anti-pseudomonas psl and pcrv binding molecules: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.... Agent:

20150023965 - Methods of treating urothelial carcinoma: Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed.... Agent: Foundation Medicine, Inc.

20150023968 - Compositions and methods for diagnosing and treating hyperthyroidism in companion animals: An isolated DNA molecule comprising a fragment of the gene encoding the feline NIS is disclosed as well as methods of use thereof. Also provided are methods for rational diet design of food composition suitable for administration to feline companion animals afflicted with hyperthyroidism, comprising (a) accessing at least one... Agent:

20150023970 - Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy: In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.... Agent: Acceleron Pharma Inc.

20150023976 - Antibody polypeptides that antagonize cd40l: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK... Agent: Domantis Limited

20150023972 - Combination pharmaceutical composition and methods of treating and preventing the infectious diseases: The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different... Agent:

20150023971 - Modulation of activity of proneurotrophins: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as... Agent: H Lundbeck A/s

20150023975 - Par-1 activation by metalloproteinase-1 (mmp-1): Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1... Agent:

20150023973 - Pharmaceutical compositions for preventing or treating angiogenic diseases comprising inhibitors of nup153 gene expression or nup153 activity as active ingredient: The present invention provides a pharmaceutical composition for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient and a method for screening an agent for preventing or treating angiogenic diseases. According to the present invention, inhibition of the NUP153 gene expression or... Agent:

20150023969 - Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.... Agent: Epitopix, LLC

20150023974 - Toll-like receptor 2 binding epitope and binding member thereto: The present invention relates to the identification of a TLR2 binding epitope wherein binding of a binding member to the epitope serves to inhibit TLR2 activation and/or signalling. Polypeptide fragments of TLR2 and three-dimensional structures comprising one or more amino acid residues His318, Pro320, Gln321 or Arg321, Tyr323, Lys347, Phe349,... Agent:

20150023977 - Protein formulations and methods of making same: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are... Agent: Abbvie Inc.

20150023978 - Anti mif antibodies: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain... Agent: Baxter Healthcare Sa

20150023979 - Antibodies against e7 protein of human papilloma virus (hpv): The invention discloses a method for preparing Human Papilloma Virus protein E7 antigen (HPV E7 antigen) comprising the following steps: —providing a purified preparation of HPV protein E7; —phosphorylating the HPV protein E7 in the preparation; —purifying the phosphorylated E7 protein with an anion exchange chromatography, wherein the phosphorylated E7... Agent: Valdospan Gmbh

20150023980 - Combination pharmaceutical composition and methods of treating and preventing the infectious diseases: The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different... Agent:

20150023981 - Method of treatment and agents useful for same: The present invention relates generally to a method of modulating graft functionality. More specifically, the present invention relates to a method of downregulating the onset or progression of graft dysfunction by downregulating the functional level of activin. The method of the present invention is useful, inter alia, in the treatment... Agent: Paranta Biosciences Limited

20150023982 - Methods of administering anti-tnfalpha antibodies: Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g.,... Agent: Abbvie Biotechnology Ltd.

20150023983 - Recombinant vapa and vapc peptides and uses thereof: The present invention provides a recombinant protein comprising consecutive amino acids, the sequence of which is substantially identical to a sequence of amino acids present in a Rhodococcus equi virulence-associated protein and compositions containing fusion proteins of the invention. The present invention also provides uses of the compositions in the... Agent: Santa Cruz Biotechnology, Inc.

20150023985 - Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition: The present invention is concerned with a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine and method for treating and preventing upper respiratory tract conditions or... Agent:

20150023984 - Genetic alterations associated with type i diabetes and methods of use thereof for diagnosis and treatment: Compositions and methods for the detection and treatment of T1D are provided.... Agent: The Children's Hospital Of Philadelphia

20150023986 - Modulation of tim receptor activity in combination with cytoreductive therapy: A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family... Agent:

20150023987 - Immunogenic compositions and reagents for preparing: The invention described herein pertains to compounds and conjugates, to compositions, complexes and formulations comprising the compounds and/or conjugates, and to methods of use of the compounds, conjugates and their compositions, complexes and formulations in vaccines and vaccinations and generating immune responses.... Agent: Purdue Research Foundation

20150023989 - New antibody drug conjugates (adcs) and the use thereof: The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for... Agent:

20150023988 - Potent and selective inhibitors of nav1.7: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic... Agent: Amgen Inc.

20150023990 - Alkoxy substituted imidazoquinolines: Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are... Agent: 3m Innovative Properties Company

20150023993 - Combination therapy using active immunotherapy: The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex... Agent:

20150023991 - Means and methods for treating or diagnosing idh1 r132h mutant-positive cancers: The present invention concerns the field of tumor therapeutics and diagnostics. Specifically, it relates to a peptide comprising at least 8 amino acids in length which are present as contiguous amino acid sequence in the human Isocitratdehydrogenase Type 1 (IDH1), wherein said peptide has at least one amino acid exchange... Agent:

20150023994 - Recombinant ganoderma lucidium immunomodulatory protein (rlz-8) and uses thereof: Provided are the use of the recombinant Ganoderma lucidum immunomodulatory protein (rLZ-8) for the manufacturing of a medicament for antitumor, increasing leukocyte and inhibiting immunological rejection and the pharmaceutical composition comprising the rLZ-8 protein, wherein the rLZ-8 protein is expressed from pichia yeast.... Agent:

20150023992 - Timothy grass allergens and methods and uses for immune response modulation: The invention relates to Timothy Grass proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of Timothy Grass proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic... Agent:

20150023996 - Polynucleotides for treating oncogenic viral polypeptide positive tumors: This document relates to polynucleotides encoding antigenic polypeptides to induce an immune response to oncogenic viral polypeptides. Also provided are compositions comprising polynucleotides encoding antigenic polypeptides, and methods of use. In the provided methods, the virus can be a human papilloma virus. In some embodiments, a method for killing a... Agent:

20150023995 - Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of... Agent: Takeda Vaccines, Inc.

20150023997 - Compositions, methods and therapies for administering antigen peptide: The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with Propionibacterium acnes. The compositions include a combination of peptide and anti-TNF. The peptide consists of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived the specific amino... Agent: Hasumi International Research Foundation

20150024000 - Multivalent vaccine protection from staphylococcus aureus infection: Vaccine formulations effective against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) are disclosed, as well as methods of using the vaccine formulations in the treatment and prevention of Staphylococcus aureus infections in a subject.... Agent: University Of Maryland, Baltimore

20150023999 - Novel targets of acinetobacter baumannii: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies... Agent:

20150023998 - Stable anthrax vaccine formulations: Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against anthrax infection.... Agent: Emergent Biosolutions Inc.

20150024001 - Molecular mimic mucosal aids vaccine: The present invention addresses the problem of providing an AIDS vaccine whereby mucosal immunity can be induced, the immune system can be defended against breakdown by HIV infection, HIV can be prevented from escaping the immune system by being highly mutable, and rapid HIV infection can be prevented. According to... Agent: National University Corporation Kumammoto University

20150024002 - Alphavirus vectors for respiratory pathogen vaccines: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as... Agent:

20150024003 - Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in... Agent:

20150024004 - Flavivirus vaccines: The invention provides flavivirus vaccines and methods of making and using these vaccines.... Agent:

20150024005 - Augmentation of titer for vaccination in animals: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.... Agent: Omnigen Research, L.L.C.

20150024006 - Allogeneic cellular immunotherapy for opportunistic infection: A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion.... Agent:

20150024007 - Long term disease modification using immunostimulatory oligonucleotides: The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification.... Agent:

20150024008 - Methods and compositions involving induced senescent cells for cancer treatment: Disclosed are cancer vaccines comprising senescent cells and methods of using and preparing the vaccines.... Agent:

20150024009 - Genetically modified organism for the production of lipids: The invention provides an isolated genetically modified non-mammalian organism, wherein the activity of acyl-CoA:sterol acyltransferase/sterol O-acyltransferase (EC 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol O-acyltranferase (EC 2.3.1.20) and/or lecithin cholesterol acyl transferase/phospholipid: diacylglycerol acyltransferase (EC 2.3.1.158) and/or acyl CoA-wax alcohol acyltransferase (EC 2.3.1.75) is reduced or abolished in comparison with a corresponding wildtype... Agent: Organobalance Gmbh

20150024012 - Article and methods for oral self-administration of nicotine: The invention discloses an article for swaddling in the mouth to deliver pharmacologically active substances, particularly nicotine, in combination with dyes or flavorings, across the buccal membranes when said article is swaddled in the mouth. The article comprises a non-edible substantially cylindrical core element, such as a toothpick, and the... Agent:

20150024013 - Capsule and powder formulations containing lanthanum compounds: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical... Agent:

20150024010 - Methods of therapeutic treatment of eyes: Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or... Agent:

20150024011 - Use of exosomes to promote or enhance hair growth: We describe the use of an exosome for the preparation of a pharmaceutical composition to promote or enhance would healing or hair growth, or both, in an individual. The exosome may be derived from a stem cell such as a mesenchymal stem cell (MSC).... Agent:

20150024015 - Aqueous suspension of composite silicone powder, w/o emulsion and cosmetics: The invention relates to aqueous suspension of composite silicone powder, W/O emulsion and cosmetics, providing an aqueous suspension of composite silicone powder comprising: (A) a composite cured silicone powder comprising (a) a cured silicone powder, (b) an inorganic fine powder coated on the surface of said cured silicone powder, (c)... Agent:

20150024016 - Skincare product and method of preparation thereof: This invention discloses a novel class of skincare products to remove iron in the skin and its preparation method. The core active components, termed as de-ironizing inducers (DII), consist of a reducing agent and a precipitating agent. The reducing agent is selected from vitamin C, vitamin E, glutathione, vitamin A,... Agent:

20150024014 - Treatment of disease with poly-n-acetylglucosamine nanofibers: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue,... Agent: Marine Polymer Technologies, Inc.

20150024017 - Compositions and methods for cell killing: A solid buffer including one or more ion exchange materials, wherein said solid buffer has a volumetric buffering capacity greater than about 20 mM H+/(L·pH unit) and further wherein, when said material is in an environment capable of transporting H+ ions, said solid buffer is adapted to cause the death... Agent: Oplon Pure Science, Ltd.

20150024018 - Anti-infective antimicrobial-containing biomaterials: A material including a plurality of fatty acid chains cross-linked together and a silver fatty acid salt formed with the fatty acid chains within the material. Methods for forming a material are also included. The silver-containing materials can be utilized alone or in combination with a medical device for the... Agent: Maquet Cardiovascular LLC

20150024019 - Antimicrobial-coated medical articles: The disclosure provides polymers having antimicrobial activity and articles with the polymers coated thereon. The polymers include a first pendant group comprising a first cationic component, a second pendant group comprising a nonpolar component, and a third pendant group comprising an organosilane component. The disclosure also includes methods of coating... Agent:

20150024020 - Drug delivery system and method of manufacturing thereof: An apparatus and method provides a drug layer formed on a surface region of a medical device, the drug layer comprised of a drug deposition and a carbonized or densified layer formed from the drug deposition by irradiation on an outer surface of the drug deposition, wherein the carbonized or... Agent:

20150024022 - Hydrogel implants with varying degrees of crosslinking: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with... Agent:

20150024021 - Method for treating a periodontal disease: A method for treating a periodontal disease affecting a periodontal pocket of a patient. The method comprises inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled release solid... Agent:

20150024023 - Calcium phosphate material: The invention relates to porous granular calcium phosphate osteoinductive materials, particularly materials useful in body tissue repair, principally bone repair and bone replacement, and also to the use of such materials and to a method of making such materials. Exemplary materials comprise discrete porous granules each containing crystals of at... Agent: Sirakoss Limited

20150024024 - Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof: Cells and cell lines that are genetically modified to express the hCox-2 enzyme, which results in the upregulation of prostaglandin F2 alpha (PGF2a) on the cells have been obtained. Encapsulated cell therapy devices containing such cells or cell lines that are capable of delivering PGF2a, as well as methods of... Agent: Neurotech Usa, Inc.

20150024025 - Aligned nanofibrous structures for axonal regeneration after spinal cord injury or surgery: Embodiments of the present disclosure provide for aligned nanofibrous polymer matrix structure, structures incorporating aligned nanofibrous polymer matrix structures, methods of using aligned nanofibrous polymer matrix structures, methods of making aligned nanofibrous polymer matrix structures, and the like.... Agent: The Uabb Research Foundation

20150024027 - Bioswellable sutures: Bioswellable sutures are provided in the form of absorbable, compliant monofilaments of an amphiphilic copolyester, an absorbable multifilament braid, a non-absorbable monofilament with swellable outer layer, a non-absorbable multifilament braid with an absorbable monofilament core of an amphiphilic copolymer, and a non-absorbable, multifilament braid molecularly integrated with an outer sheath... Agent: Poly-med, Inc.

20150024026 - Scaffolds for cell transplantation: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release... Agent: President And Fellows Of Harvard College

20150024028 - Transdermal therapeutic system having improved long-term wearing comfort: The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterised in that they are able to continuously adhere to the surface of the skin over a long period of time.... Agent:

20150024029 - Composition and dressing with nitric oxide: A dressing composition for use as a skin dressing comprises an elastomeric-adhesive composition, and a zeolite comprising releasably adsorbed nitric oxide. The zeolite may comprise a transition metal cation such as Co, Fe, Mn, Ni, Cu, Zn, Ag or a mixture thereof as an extra-framework metal cation, preferably Zn. The... Agent:

20150024040 - Administration regime for n-hydroxy-4-benzamide: or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days... Agent:

20150024039 - Blood vessel permeability-enhancement for the treatment of vascular diseases: This invention relates to methods of enhancing the permeability of blood vessels to therapeutic agents.... Agent:

20150024038 - Immunogenic compositions and methods: The invention is directed to immunogenic compositions and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating the symptoms of one or more microbial infections, including, for example, influenza.... Agent:

20150024033 - Method and system for synthesizing nanocarrier based long acting drug delivery system for buprenorphine: The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of buprenorphine and a method of synthesising the same. The buprenorphine entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is... Agent: Kimia Zist Parsian Co

20150024034 - Method and system for synthesizing nanocarrier based long acting drug delivery system for dexamethasone: The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of dexamethasone and a method of synthesising the same. The dexamethasone entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is... Agent: Kimia Zist Parsian Co

20150024035 - Method and system for synthesizing nanocarrier based long acting drug delivery system for methadone: The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of methadone and a method of synthesising the same. The methadone entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is... Agent: Kimia Zist Parsian Co

20150024031 - Methods and compositions for reducing pain, inflammation, and/or immunological reactions associated with parenterally administering a primary therapeutic agent: Disclosed herein are methods and pharmaceutical compositions for reducing the pain associated with parenterally administering a therapeutic agent. The methods and compositions comprise a dispersion comprising microparticles of an analgesic agent in an amount effective to reduce the pain, inflammation, and/or immunological reaction associated with parenterally administering a primary therapeutic... Agent: Baxter Healthcare Sa

20150024032 - Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia: Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention,... Agent:

20150024030 - Protection against and treatment of ionizing radiation: Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds, and prevents accumulation of one or more toxic compounds,... Agent:

20150024036 - Targeting rnas to microvesicles: Disclosed herein is an isolated nucleic acid molecule comprising a first nucleic acid sequence 5′-ACCCTGCCGCCTGGACTCCGCCTGT-3′ (SEQ ID NO: 22), or a functional variant thereof, operably linked to a second, heterologous nucleic acid sequence. The isolated nucleic acid molecule can be DNA (in an expression vector) and RNA (mRNA, shRNA, orncRNA).... Agent: The General Hospital Corporation

20150024037 - Xenoantigen-displaying anti-cancer vaccines and method of making: Compositions, methods of making, and methods of using, xenoantigen-displaying anticancer vaccines are described. In another broad aspect, there is provided herein a method of synthesizing an alkynefunctionalized composition of claim 1, comprising: deprotecting an ester comprising a Fmoc moiety to form a free acid; coupling the free acid of step... Agent: The University Of Toledo

20150024041 - Health supplement using guarana extract: The current invention is a supplement made from a combination of herbs, vitamins, amino acids which in the preferred embodiment is a 100% vegetarian liquid capsules that are ingested allow for rapid absorption. The components of the supplement can be mint or menthol such as peppermint or spearmint, Methyl B12... Agent:

20150024042 - Phased dosing of clopidogrel: The present invention provides for novel formulations of clopidogrel to provide for phased/spaced release for use as improved antiplatelet therapies in stroke and cardiovascular indications.... Agent: Pozen Inc.

20150024043 - Medi-cap (bio-absorbable capsules): Medi-Cap a specialized absorbable capsule of various shapes and sizes. It may come prefilled with desired medication or material or it can come in a two-piece snap together capsule that can be filled with desired medication/material by the medical professional. (Most Likely prefilled) Medi-Cap will be time released meaning that... Agent:

20150024044 - Gastric reflux resistant dosage forms: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin... Agent:

20150024045 - Liquid-filled hard gel capsule pharmaceutical formulations: Embodiments of liquid-filled hard gel capsule pharmaceutical formulations comprise a non-emulsified mixture, wherein the non-emulsified mixture comprises about 0.1 to about 5% by weight of at least one active pharmaceutical ingredient, about 50 to about 95% by weight long chain triglycerides, and about 5 to about 25% by weight medium... Agent: Mylan Inc.

20150024046 - Abuse-proofed oral dosage form: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary... Agent: Gr&#xdc Nenthal Gmbh

20150024047 - Pharmaceutical composition and administrations thereof: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.... Agent:

20150024048 - Controlled release pharmaceutical compositions for prolonged effect: the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer, and the composition having a cylindrical form optionally with one or more... Agent:

20150024049 - Controlled release pharmaceutical compositions comprising a fumaric acid ester: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that... Agent: Forward Pharma A/s

20150024056 - Controlled release sterile injectable aripiprazole formulation and method: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle thereof, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A... Agent: Otsuka Pharmaceutical Co., Ltd.

20150024050 - Dry powder formulations of dnase i: DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.... Agent:

20150024055 - Enhanced immediate release formulations of topiramate: The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine.... Agent: Supernus Pharmaceuticals, Inc.

20150024051 - Injectable hydrogel system to modulate host response at bone implant interface: A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be... Agent:

20150024052 - Nitric oxide releasing pharmaceutical compositions: The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same.... Agent: Novan, Inc.

20150024054 - Solid pharmaceutical dispersions with enhanced bioavailability: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment.... Agent: Bend Research, Inc.

20150024053 - Topical wound treatment method and composition: A topical wound treatment composition comprises a hydrogen peroxide generator; alkaline powder; not more than 5 percent by weight of water; additional topical active agent if desired, and emollient (preferably hygroscopic emollient) to balance. When topically applied to a wound and water from the surrounding environment diffuses into the composition,... Agent:

20150024057 - Non-digestible sugar-coated products and process: A method and composition are provided for coating a component to achieve colon-targeted delivery. A component is coated with a fructose-based non-digestible carbohydrate such as a inulin, fructo-oligosaccharide or neosugar. The coated component is orally administered to a monogastric animal. The non-digestible coating causes the composition to pass through the... Agent:

20150024059 - Modified release formulations containing drug - ion exchange resin complexes: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix.... Agent:

20150024058 - Pharmaceutical compositions for the deterrence and/or prevention of abuse: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from... Agent:

20150024060 - Nutraceuticals having sustained release for improved bioavailability and method of production: The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of... Agent: Bioactives LLC

20150024061 - Alloplastic injectable dermal filler and methods of use thereof: A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material... Agent:

20150024062 - Medical food for the dietary management of major depression: The present invention relates to medical food for the dietary management of major depression comprising a water containing from 0.0002 to 0.0278 mol. % of isotopologue HOD, preferably, from 0.0178 to 0.0278 mol. % of isotopologue HOD.... Agent:

20150024063 - Multi-phased, biodegradable and oesteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone: Methods and apparatuses are provided for musculoskeletal tissue engineering. For example, a scaffold apparatus is provided which comprises microspheres of selected sizes and/or composition. The microspheres are layered to have a gradient of microsphere sizes and/or compositions. The scaffold provides a functional interface between multiple tissue types.... Agent: The Trustees Of Columbia University In The City Of New York

20150024064 - Pka buffered vitamin c composition and method: A pKa buffered vitamin C composition which includes a base alkalizer composition mixed with vitamin C (calcium ascorbate or ascorbic acid). The base alkalizer composition can be approximately 24% to 40% and the ascorbic acid or calcium ascorbate can be approximately 76% to 60% by weight of the vitamin C... Agent:

20150024065 - Treatment of retroviral reservoirs exploiting oxidative stress: Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of... Agent:

20150024066 - Methods for preventing or treating excess weight using oxyntomodulin: Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake.... Agent: Imperial Innovations

20150024067 - Ingestible canker sore treatment: A treatment and prevention formulation for canker sores of the oral cavity including an aqueous alkaline solution having at least three B vitamins and zinc (provided as Zn (II) EDTA alkali metal salt) mixed therein and administered to a target area by a spray container. The vitamins are B6, B9... Agent:

20150024069 - Compositions and methods for treatment of hemorrhage: Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may... Agent:

20150024068 - Dialysis composition comprising citrate, calcium and magnesium: Dialysis fluid compositions including 0.5 to 3 mM citrate, 1 to 5 mM total calcium, and 0 to 1.5 mM total magnesium. These dialysis fluid compositions include 0.10 to 0.2 mM more total calcium per 1 mM citrate within the dialysis fluid as compared to the calcium concentration ordinarily prescribed... Agent:

20150024070 - Ingestible canker sore treatment: A treatment and prevention formulation for canker sores of the oral cavity including an aqueous alkaline solution having at least three B vitamins, zinc and iron mixed therein and administered to a target area by a spray container. The vitamins are B6, B9 and B12, but may include other vitamins... Agent:

20150024071 - Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders: The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of... Agent: Merck Sharp & Dohme Corp.

20150024073 - Compositions containing extracts of malva neglecta: The present invention relates to a skin care composition comprising an extract of Malva neglecta and a cosmetically acceptable topical carrier. Non-polar and/or lipophilic extracts have been found to be particularly effective in improving skin barrier function, improving the appearance of at least one sign of aging in skin, and/or... Agent: Johnson & Johnson Consumer Companies, Inc.

20150024074 - Methods for treating skin barrier and reducing acne: A method of treating acne by applying to the skin an extract of Malva neglecta topically to the area of skin affected by acne to increase ceramide production at the area of skin affected by acne to treat and/or improve the acne. Additionally, cholesterol may also be applied to the... Agent:

20150024072 - Methods of treating a skin condition with malva neglecta: The present invention relates to a method of treating a skin condition, particularly improving skin barrier function, improving the appearance of at least one sign of aging in skin, and/or lightening skin, by applying to the skin an extract of Malva neglecta topically to the skin in need of treatment.... Agent: Johnson & Johnson Consumer Companies, Inc.

20150024075 - Phytocomposition for the treatment of pain related to joint diseases: It is disclosed a phytocomposition which includes: (a) 0.01 wt % to 26 wt % of Arnica montana extract; (b) 0.01 wt % to 26 wt % of Rosmarinus officinalis extract; (c) 0.01 wt % to 26 wt % of Zingiber officinale extract; and (d) 0.01 wt % to 26... Agent:

20150024076 - Methods and compositions for enhancing hair quality using blackberry extract: Compositions and methods for inducing hair growth and improving hair quality utilizing extracts of blackberry in an amount effective to induce hair growth when applied topically to an area of the skin on which hair growth is desired.... Agent:

20150024077 - Composition for treating skin barrier and reducing acne: A composition for applying to skin suffering from acne to treat the acne, the composition comprising an extract of Malva neglecta. The Malva neglecta increases ceramide production at the area of skin affected by acne to treat and/or improve the acne. Additionally, the composition may include cholesterol.... Agent:

  
01/15/2015 > 180 patent applications in 104 patent subcategories.

20150017091 - Detection and treatment of metastatic disease: The establishment and growth of metastatic tumors can be detected and inhibited by the methods and compositions described herein. As illustrated herein, agents that inhibit the expression or activity of versican, for example, in bone marrow cells effectively halt the growth and establishment of metastatic tumors at distal sites from... Agent:

20150017092 - Devices and methods for determining sensitivity to radiation: Systems and methods for determining the sensitivity of cells (and/or a subject) to ionizing radiation are provided. The systems can comprise a microfluidic device comprising a plurality of microfluidic cavities each configured to contain cells; a source of ionizing radiation configured to deliver ionizing radiation to cells in the microfluidic... Agent:

20150017093 - Radiolabeled bile acids and bile acid derivatives: The present invention relates in one aspect to radiolabeled compounds comprising the structure of Formula 1. The radiolabeled compounds are preferably bile acids or bile acid derivatives. Further aspects of the invention relates to use of the compounds comprising the structure of Formula 1 in imaging methods such as for... Agent: Region Midtjylland

20150017096 - Her3 inhibitor for modulating radiosensitivity: The present invention relates to the use of an inhibitor of HER-3 for the treatment of a hyperproliferative disease in combination with radiation treatment.... Agent:

20150017095 - Prostaglandin e2 dual variable domain immunoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent:

20150017094 - Zirconium-radiolabeled, cysteine engineered antibody conjugates: e

20150017097 - Sincalide formulations: The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using... Agent: Bracco Diagnostics Inc.

20150017098 - Carrier that targets fucosylated molecule-producing cells: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc.... Agent:

20150017099 - Diagnosis and treatment for respiratory tract diseases: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by... Agent:

20150017100 - Oral preparation useful in measuring capacity to metabolize pyridine: An object of the present invention is to provide an oral preparation that can be used to diagnose the existence or degree of pyridine metabolic capacity disorder, pyrimidine metabolic rate, etc., with high accuracy and with little variation due to individual differences. The oral preparation is prepared using a powder... Agent:

20150017102 - Cobalt-based mri contrast agent and imaging system: Novel, non-toxic cobalt-based contrast and imaging agents for use in enhanced medical imaging modalities and processes are described, as well the manufacture of markers containing such contrast agents is described, and uses for such imaging markers and contrast agents in a variety of therapeutic applications and devices.... Agent:

20150017101 - Device for the diagnosis of inflammatory tissues in dental applications: The document proposes a diagnostic chewing gum for identifying the presence of inflammatory tissues in the mouth, in particular in or adjacent to the mandible, the maxilla, an implant or the teeth of a user, comprising a base material or particles (3) embedded and/or attached to said base material; an... Agent: Thommen Medical Ag

20150017103 - Compositions with modulating agents: The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless... Agent: Foamix Ltd.

20150017104 - Compositions, methods & systems for respiratory delivery of two or more active agents: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within... Agent:

20150017106 - Agent for improving aroma intensity and/or aroma quality: The present invention provides an agent for enhancing aroma intensity and/or aroma quality of a flavor composition to be added to a food, drink, pharmaceutical product, oral care product, or the like, the agent comprising γ-aminobutyric acid and naringenin, as well as a method for enhancing aroma intensity and/or aroma... Agent: Takasago International Corporation

20150017105 - Anhydrous hydrogel composition and delivery system: The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients.... Agent:

20150017107 - Multicomponent oral care composition: The present invention relates to a multicomponent oral health care composition, comprising a source of a fluoride ion, a source of a calcium ion, a source of a phosphate ion, and stabilised chlorine dioxide, that can be used as a toothpaste, oral spray or a mouth wash/oral rinse formulation. The... Agent:

20150017108 - Method of inhibiting the formation of dental plaque: e

20150017109 - Phototherapeutic near ir fluorescent light filters: Ophthalmic lenses and light filters containing special additives that have fluorescence emission in the near infrared region of wavelengths—in order to enhance phototherapy for the human eye when it is exposed to sunlight and artificial lighting.... Agent: Photoprotective Technologies, Inc

20150017110 - Two component interactive emulsion product: The present invention describes, in one aspect, the use of two oppositely charged surfactants as the primary emulsifiers in two separated parts of a product. The emulsifiers are chosen such that when the two parts of the emulsion product are mixed, the emulsifiers react to form water insoluble compounds that... Agent:

20150017111 - Novel compound having skin-whitening, anti-oxidizing and ppar activities and medical use thereof: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention... Agent:

20150017112 - Agent for temporarily deforming keratin fibers based on a combination of specific film-forming polymers: A cosmetic agent, containing in a cosmetically acceptable carrier: a) at least one copolymer A of allyl methacrylate with one or more monomers selected from acrylic acid, methacrylic acid, acrylic acid esters and methacrylic acid esters, b) at least one polymeric quaternary ammonium compound from the group of quaternized celluloses,... Agent:

20150017113 - Product for temporarily shaping keratin fibers on the basis of a combination of specific film-forming polymers: A cosmetic agent, containing in a cosmetically acceptable carrier a) at least one copolymer (A) of allyl methacrylate with one or more monomers selected from acrylic acid, methacrylic acid, acrylic acid esters and methacrylic acid esters, b) at least one polymeric quaternary ammonium compound (B) from the group of vinylpyrrolidone... Agent:

20150017114 - New silicone acrylate and trifluoroethyl methacrylate polymer, preparation and use thereof in cosmetics: An anionic polyelectrolyte resulting from the polymerization, for 100% by mass of: a) a mass ratio ≧70% and ≦98.5% of monomeric units from a monomer with a strong acid function; b) a mass ratio ≧0.5% and ≦10%,—either of a monomer of formula (1a) : R—(CH2)3-Si(CH2)2-[0-Si(CH3)2-]nO—Si(CH3)2—(CH2)3—R (1a), wherein R represents the... Agent:

20150017115 - Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof: Polymeric conjugates of a polymeric backbone formed of a plurality of backbone units and having attached to portions of the backbone units two or more therapeutically active agents, or one or more therapeutically active agents and a NCAM targeting moiety, are disclosed. Uses of such polymeric conjugates in treating and/or... Agent:

20150017116 - Methods for treating arthropods: Methods for treating arthropods comprising depositing at least one drop of a liquid formulation containing at least one surfactant on a solid surface of an arthropod at a contact angle sufficient to cause rapid and enhanced knockdown (KD) of the arthropod. The contact angle comprises an angle formed between a... Agent:

20150017117 - Composition for in vivo vessel repair: The present invention relates to a biocompatible polymer composition, suitable for in vivo vessel repair, comprising a matrix pre-polymer, a filler and a curing agent, wherein said composition wherein said biocompatible polymer composition is curable in the presence of a curing catalyst at 37° C. to form a cured material... Agent:

20150017118 - Molded or extruded cork composite and method of manufacturing compressed cork pet products and pet toys made from the same: A cork-catnip composite material is provided that is capable of being molded, compressed, extruded or similarly processed into small or large bodies or sheets and allow for the economic manufacture of a variety of products for domestic pets, especially felines. Dried and granulated catnip (or similar olfactory attractant) is blended... Agent: Ourpet's Company

20150017119 - Methods for diagnosis, prognosis and methods of treatment: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that... Agent: Nodality, Inc.

20150017121 - Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an... Agent: Universitat Zurich

20150017122 - Conditioned medium obtained from placental mesenchymal stem cells and use thereof in the therapeutic treatment of preeclampsia: It is described a conditioned medium (CM) obtainable by culturing, in a liquid culture medium, placental mesenchymal stem cells isolated from the placental tissue of pregnant women not affected by preeclampsia. The conditioned medium of the invention includes at least IL-6, IL-10 and MCP-1 proteins and it is effective for... Agent: Corion Biotech S.r.l.

20150017123 - Il-1 family variants: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.... Agent:

20150017120 - Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy: The present invention provides a method of enhancing adoptive cell therapy (ACT) by administering an extended-pharmacokinetic (PK) interleukin (IL)-2 to a cancer subject receiving ACT, optionally in combination with a therapeutic antibody. Methods of treating cancer and promoting tumor regression are also provided.... Agent:

20150017124 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent:

20150017125 - Biocontrol microorganisms: Methods, devices, and compositions described herein are directed to artificially evolving an organism for use as a biocontrol agent. Methods, devices, and compositions described herein are useful for evolving a microorganism to acquire traits not naturally associated with the microorganism. The artificial evolution process can utilize culture methods and devices... Agent:

20150017126 - Poxviral oncolytic vectors: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.... Agent: Transgene S.a.

20150017127 - Selective cell targeting using adenovirus and chemical dimers: Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.... Agent: Salk Institute For Biological Studies

20150017138 - Bacterial mediated thf alpha gene silencing: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium... Agent:

20150017137 - Drug resistant immunotherapy for treatment of a cancer: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs... Agent:

20150017136 - Methods for engineering allogeneic and highly active t cell for immunotherapy: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of... Agent: Cellectis

20150017139 - Methods of generating neural stem cells: The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated... Agent:

20150017140 - Organoids comprising decellularized and repopulated placental vascular scaffold: Provided herein are organoids comprising decellularized placental vascular scaffold comprising, or consisting of, a decellularized placental vascular scaffold, and methods of making and using the same.... Agent: Anthrogenesis Corporation

20150017141 - Use of icos-based cars to enhance antitumor activity and car persistence: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.... Agent: The Trustees Of The University Of Pennsylvania

20150017128 - Strains of lactic acid bacteria and/or bifidobacteria inhibiting/reducing the growth of different biotypes of e. coli and different biotypes of clostridia: The present disclosure refers to strains of lactic bacteria and/or bifidobacteria having activity of inhibiting/reducing the growth of different biotypes of E. coli, including E. coli 0157:7 and different biotypes of clostridia, including Clostridium difficile, Listeria monocytogenes, Enterococcus sp. and Klebsiella sp. Furthermore, the present invention refers to a pharmaceutical... Agent:

20150017142 - Composition comprising probiotic bacteria for use in the treatment of immune disorders: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.... Agent: Probiotical S.p.a.

20150017143 - Composition comprising specific lactobacillus helveticus strains and reducing food and/or respiratory allergy symptoms: A composition comprising specific Lactobacillus helveticus strains is provided for reducing the symptoms of allergies originating from food, respiratory or contact allergens. Preferably the composition reduces symptoms of allergies (secondary prevention) while also able to reduce sensitization (primary prevention).... Agent:

20150017144 - Compositions for the treatment of clostridium difficile associated disease, methods of their use and methods of making the same: Provided herein are compositions useful for the treatment or prevention of C. difficile-associated disease or C. difficile-associated diarrhea in a subject in need thereof, and delivery systems and package systems comprising the same. Also provided are methods using the compositions, delivery systems, package systems and methods of making the same.... Agent:

20150017134 - Emt-inducing transcription factors cooperate with sox9: In some aspects, compositions and methods useful for generating stem cells from epithelial cells are disclosed.... Agent:

20150017131 - Hair follicles made ex vivo that can be inserted into a recipient for hair restoration: The present invention recognizes that there exists a long felt need for reliable hair growth methods and compositions that do not suffer from side effects and limitations of current technologies, such as surgery using a subject's own hair and pharmaceutical compositions. A first aspect of the present invention is a... Agent:

20150017135 - In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted... Agent:

20150017132 - Mesenchymal stem cells and uses therefor: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.... Agent:

20150017130 - Methods and compositions for inhibition of immune responses: Methods and compositions for modulating immune responses are provided herein.... Agent:

20150017133 - Phenotype profile of human retinal progenitor cells: The present invention relates to substantially homogenous populations of human retinal progenitor cells having the following positive surface markers: SSEA4, CD73, PTK7 and PSA-NCAM. The invention also relates to method for preparing such substantially homogeneous cell populations from human tissue using cell sorting techniques.... Agent:

20150017129 - Preservation of the biological activity of undenatured type ii collagen: The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis... Agent:

20150017145 - Pharmaceutical kits comprising mesenchymal stem cells: A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration... Agent: Recellerate, Inc.

20150017146 - Method of enhancing efficacy of blood transfusions: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.... Agent: The Regents Of The University Of California

20150017147 - Methods and products to provide oral nutritional care to subjects with dementia: The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total... Agent: D&e Gillespie Enterprises LLC

20150017148 - Netrin loop peptide mimetics and uses thereof: In certain embodiments compositions are provided that comprise a pentapeptide comprising the formula: C1-X2-X3-X4-C5 where C1 and C5 are independently selected cysteines or cysteine analogues, or other amino acids with sidechains suitable for cyclization, where the cysteines or cysteine analogs are attached to each other by a linkage that does... Agent:

20150017150 - Methods, compounds, and compositions for treatment and prophylaxis in the respiratory tract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a... Agent:

20150017149 - Pharmaceutical or nutritional compositions containing galactosidase, and their use: The present disclosure relates to pharmaceutical or nutritional compositions containing α-galactosidase and β-galactosidase and their use in the prevention and/or treatment of gastroesophageal reflux disease; in particular the present disclosure related to pharmaceutical or nutritional compositions.... Agent:

20150017151 - Pharmaceutical formulations of xanthine or xanthine derivatives, and their use: The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.... Agent:

20150017152 - Composition containing 4-oxovaleric acid and leuconostoc/radish root ferment filtrat: A composition comprising 4-oxovaleric acid present in an amount of 0.05 to 1% by weight (as supplied) of the composition and leuconostoc/radish root ferment filtrate present at 0.2 to 2% by weight (as supplied) of the composition.... Agent:

20150017155 - Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof: The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such... Agent: Biogen Idec Ma Inc.

20150017154 - Anti-nerve growth factor antibodies and methods of preparing and using the same: A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralise the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic... Agent: Nvip Pty Ltd.

20150017160 - Combinations and uses thereof: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.... Agent: Morphosys Ag

20150017156 - Esx-mediated transcription modulators and related methods: The present invention relates to gene regulation. In particular, the present invention provides small compounds capable of modulating ESX-mediated transcription and related methods of therapeutic and research use. In addition, the present invention provides methods for treating conditions associated with aberrant EGFR expression with ESX-mediated transcription modulators (e.g., ESX-mediated transcription... Agent: The Regents Of The University Of Michigan

20150017157 - Methods for treating acne: The present disclosure relates to methods and materials for treating acne in a subject including, for example, moderate and/or severe acne, using anti-IL-1β binding molecules such as an anti-IL-1β antibody or binding fragment thereof.... Agent:

20150017153 - Monoclonal antibodies that neutralize anthrax toxins: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies.... Agent:

20150017159 - Monocyte biomarkers for cancer detection: The disclosure relates to the field of biomarkers to diagnose a disease, more particularly to the field of biomarkers to diagnose cancer, and most particularly to colorectal cancer. Specifically, these biomarkers are expressed in monocytes of a subject, particularly circulating monocytes, as can be isolated from peripheral blood. The markers... Agent:

20150017158 - Tetrahydrofolates in combination with egfr-inhibitors: The present invention relates a pharmaceutical composition comprising an EGFR inhibitor and methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate, for use in the treatment of cancer. The methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate enhances the anticancer efficacy of the EGFR inhibitor. The cancers that may be treated include breast cancer, gastric cancer, gastrointestinal cancer, gall... Agent: Isofol Medical Ab

20150017164 - Combination of blys and/or april inhibition and immunosuppressants for treatment of autoimmune disease: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment... Agent:

20150017161 - Compositions and methods for the alteration of xlhed phenotypes: The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens... Agent: Edimer Pharmaceuticals, Inc.

20150017163 - Methods for treating or preventing ophthalmological conditions: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and... Agent:

20150017162 - Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same: In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least... Agent:

20150017167 - Anti-human ccr7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having... Agent:

20150017165 - Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof: Monoclonal antibodies against LRP6 and that block the Wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed.... Agent:

20150017166 - Regulation of glucose metabolism using anti-cgrp antibodies: The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance.... Agent:

20150017168 - Dual variable domain immunoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbvie Inc.

20150017169 - Sequence asymmetric modified igg4 bispecific antibodies: The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position... Agent:

20150017170 - Biomarker for selecting a subject for application of an anti-c-met antibody: A method of selecting a subject for administration of an anti-c-Met antibody, comprising (i) determining the presence or the amount of a ubiquitin peptidase, (ii) determining the presence or expression level of a ubiquitin peptidase coding gene, or (iii) measuring the activity of a ubiquitin peptidase, in a biological sample;... Agent:

20150017173 - Antibodies to human transmembrane proteins: The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.... Agent: Incyte Corporation

20150017171 - Methods and agents for the diagnosis and treatment of hepatocellular carcinoma: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.... Agent:

20150017172 - Pharmaceutical composition for treatment and/or prevention of cancer: This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of... Agent: Toray Industries, Inc.

20150017174 - Composition: The present invention relates to a composition for use in the treatment of an intestinal tract disorder caused by a gluten-associated protein, said composition comprising at least one agent which binds to the gluten-associated protein, characterized in that the composition is administered at the same time as or at most... Agent:

20150017177 - Injectable, non-aqueous suspension with high concentration of therapeutic agent: An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer... Agent: Durect Corporation

20150017176 - Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) inhibitor such as an anti-IL-4Rα antibody.... Agent:

20150017175 - Methods of administering anti-tnfalpha antibodies: Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g.,... Agent:

20150017178 - Anti-cd26 antibodies and uses thereof: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic... Agent:

20150017179 - Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one... Agent:

20150017180 - Treatment of chronic inflammatory conditions: A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient.... Agent: Csl Limited

20150017181 - Prevention of infection: The invention relates to compositions and methods to prevent enteric infection in a subject at risk of such infection. In particular, the invention relates to the prevention of recurrence of infection by Clostridium difficile.... Agent: Csl Behring Ag

20150017182 - Methods for treating nasal polyposis by administering an il-4r antagonist: The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.... Agent:

20150017183 - Single domain antibodies as inhibitors of pcsk9: Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described.... Agent:

20150017184 - Il-17 receptor antibody formulation: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.... Agent: Kirin-amgen, Inc.

20150017185 - Method to improve the immune function of t cells: The present invention provides a method for enhancing the immune function of a memory T cell which comprises the step of coinhibting signalling via an inhibitory receptor which regulates T cell exhaustion and via the p38 MAP kinase signalling pathway in the T cell, and a method for treating and/or... Agent:

20150017187 - Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use: Provided herein are antibodies comprising multiple non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.... Agent:

20150017186 - Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use: Provided are compositions and combinations containing an organophosphorus bioscavenger and a hyaluronan-degrading enzyme. The provided compositions and combinations can be used to treat or prevent organophosphorus poisoning, including nerve agent poisoning and pesticide poisoning.... Agent:

20150017188 - Cysteine engineered antibodies and conjugates: o

20150017189 - Methods of making and using nanostructures: The invention provides methods for attaching drugs, dyes or radiolabels to bis-MTX. This method can be used to prepare bis-MTX analogs that can be used to deliver agents, such as nanoparticles, drugs, dyes or radiolabels, to cells.... Agent:

20150017191 - Adjuvant formulations comprising tlr4 agonists and methods of using the same: Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.... Agent:

20150017190 - Use of epitopes inducing specific tolerance for the prevention of tissue rejection: The present invention relates to a composition for use in the prevention of the rejection of skin tissue, comprising an effective amount of a peptide comprising an epitope of an antigen selected from the group of the polypeptides type XVII collagen, VII collagen, integrin alpha 6, integrin beta 4, chains... Agent:

20150017193 - Rab6kifl/kif20a epitope peptide and vaccines containing the same: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5... Agent:

20150017192 - Site-specific chemoenzymatic protein modifications: The present invention relates to methods and reagents for use in site-selective modification of proteins having lysine residues with functionalized peptides using a chemoenzymatic microbial transglutaminase-mediated reaction. The functionalized proteins may be used for study or therapeutic uses.... Agent:

20150017196 - Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses: Described herein is the generation of optimized H5N1 and H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H5N1 and H1N1 influenza isolates.... Agent:

20150017195 - Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection: Disclosed are methods of transforming dendritic cells with a chimeric adenovirus-5 (Ad5). A chimeric adenovirus includes a fiber comprising a tail, a shaft and a knob, wherein the knob is a porcine knob, and a nucleic acid comprising a promoter operably linked to a heterologous sequence encoding an antigen peptide.... Agent: Washington University

20150017194 - Virus like particle comprising pd-1 antigen or pd-1 ligand antigen: The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc.... Agent: Vlp Therapeutics, LLC

20150017197 - Hcv vaccines and methods for using the same: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.... Agent:

20150017199 - Cholera toxin chimera and its use as a staph vaccine: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at... Agent:

20150017198 - Mutated and bacteriophage t4 nanoparticle arrayed f1-v immunogens from yersinia pestis as next generation plague vaccines: Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH2-terminal β-strand of F1 of Yersinia pestis is transplanted to the COOH-terminus of F1 of Yersinia pestis and the NH2-terminus sequence flanking the β-strand of F1 of Yersinia pestis... Agent:

20150017200 - Fusion proteins and their use in the diagnosis and treatment of leishmaniasis: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.... Agent: Infectious Disease Research Institute

20150017201 - Novel nicotine dna vaccines: The present invention provides DNA-nanostructures comprising and at least one targeting moiety, wherein the at least one targeting moiety is linked to the DNA-nanostructure; and wherein the at least one targeting moiety is nicotine or a nicotine analogue. These compounds elicit an immunogenic response in individuals and are useful as... Agent:

20150017202 - Synthetic toll-like receptor-4 (tlr-4) agonist peptides: The invention provides novel immunological adjuvants and methods for identification of such adjuvants. The invention further provides methods and compositions for eliciting an immune response to an immunogen using the novel adjuvants. The adjuvants can be employed with any suitable immunogen, including proteins, peptides, lipids, and carbohydrates. The immunogen can... Agent: Av Theapeutics, Inc.

20150017203 - Combination product for treating excess weight and/or for improving the figure: A combination product includes as active substances, at least an inhibitor of the HMG-CoA-reductase enzyme and citrulline, or a bioequivalent compound thereof, for treating excess weight or obesity and/or the accumulation of body fat. A cosmetic treatment method for improving or slimming the figure and/or for stimulating the loss of... Agent: Institut National De La Recherche Agronomique - Inra

20150017204 - Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment: The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO2, acid pH, and high osmolarity. The present invention also relates more particularly to gram-negative bacterial mutants with reduced TNF-α induction having a mutation in one or more lipid biosynthesis... Agent: Aviex Technologies LLC

20150017205 - High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer... Agent:

20150017206 - Arranging interaction and back pressure chambers for microfluidization: An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidisation device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber.... Agent: Novartis Ag

20150017207 - Methods and compositions for activation of innate immune responses through rig-i like receptor signaling: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.... Agent: University Of Washington Through Its Center For Commercialization

20150017208 - Lactic acid bacterium having immunomodulatory and anti-allergic effects: A novel lactic acid bacterium strain having immunomodulatory and anti-allergic effects in a subject is disclosed. Lactococcus lactis subsp. cremoris A17 deposited under DSMZ Accession No. DSM 27109 is disclosed. A composition including the novel lactic acid bacterium strain and a method for using the lactic acid bacterium strain are... Agent:

20150017209 - Composition for immunization against streptococcus pneumoniae: This disclosure relates to a method of preventing or treating a recurrence of acute otitis media in a subject at risk comprising administering a therapeutically effective amount of a composition, at least once to the subject. The composition administered comprises at least one immunogenic polypeptide selected from the group consisting... Agent: Sanofi Pasteur Limited

20150017211 - Delivery and formulation of engineered nucleic acids: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.... Agent:

20150017210 - Gene signature predicts adenocarcinoma prognosis and therapeutic response: The present invention is drawn to methods of predicting prognosis of, and therapeutic response in, carcinoma of the lung.... Agent:

20150017213 - Ocular composition and kits thereof: An ocular composition consisting essentially of purified water, PEG-80 sorbitan laurate, sodium trideceth sulfate, PEG-150 distearate, sodium lauroamphoacetate, cocamidopropyl hydroxysultaine, sodium laureth-13 carboxylate, sodium chloride, PEG-15 cocopolyamine, polyhexamethylene biguanide, potassium sorbate, 1,2 hexanediol, and caprylyl glycol. The composition can be applied to a fabric pad for use as an eyelid... Agent:

20150017212 - Preparation for transnasal application: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline... Agent: Shin Nippon Biomedical Laboratories, Ltd.

20150017214 - Microcapsules: A microcapsule having an average particle size of from 7.5 to 50 microns. The microcapsule contains a core and a polymeric shell enclosing the core. The core contains a core material containing an emulsifiable fragrance. The polymeric shell contains, in polymerized form, a monomer blend containing: the specific monomer (i)... Agent:

20150017215 - Cleaning wipe for use with disinfectants, method of manufacture thereof, and system: A cleaning wipe includes a dry substrate comprising nonwoven synthetic fibers, wherein the fibers have a fineness of about 2.3 denier to about 3.3 denier; and a nonionic surfactant disposed on the dry substrate, wherein the surfactant is present on the dry substrate at an add-on level of about 0.1... Agent:

20150017216 - Compositions and methods for target delivering a bioactive agent to aquatic organisms: Biodegradable and nutritionally attractive composition comprising biocidal or antibiotic compounds and/or microbes having bio-adhesion and controlled buoyancy properties are selectively fed to an aquatic organism in open or closed water-bodies, and bioactive components are released upon contact with mucosal tissues such as gill, skin or along the digestive tract of... Agent:

20150017218 - Cleansing composition having a preservative system and a wet wipe comprising the cleansing composition: A wet wipe includes a cleansing composition and a substrate. The cleansing composition includes a preservative enhancing agent selected from the group consisting of caprylyl glycol; caprylyl glyceryl ether; glyceryl caprylate; sorbitan caprylate; ethylhyexyl glycerin, and combinations thereof. The cleansing composition includes a preservative selected from the group consisting of... Agent:

20150017217 - Pesticidal compositions for insects and arthropods: The present invention provides an insect or arthropod pesticidal composition. The composition includes active ingredients having a mixture of fatty acids, each of the fatty acids having a straight carbon chain from 6 to 12 carbon atoms long. The fatty acid mixture includes a first fatty acid molecule having a... Agent: Stratacor, Inc.

20150017221 - Cell adhesion inhibitor: e

20150017222 - Disrupted cartilage products: This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes,... Agent:

20150017220 - Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair: A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo... Agent:

20150017219 - Solvent methods for preparing crystalline macrolide particulates, compositions, and articles containing particulates: The invention provides therapeutic particulates including a macrolide, such as rapamycin, in solid state crystalline form, having a size of 20 μm or less, or 10 μm or less. The particulates are formed in one method by preparing a composition with a macrolide and first (e.g., xylene) and second (e.g.,... Agent:

20150017223 - Edible coating composition and uses thereof: Described herein is an edible coating for food products in which the coatings comprises a polysaccharide cross-linked with a cross-linking agent solution. Also described herein are methods for coating food products and forming clusters of food products. The use of the edible coating for extending the shelf-life of food products... Agent: Fruitsymbiose Inc.

20150017224 - Method for producing a tissue paper sheet material containing an adjuvant substance for the treatment of allergic rhinitis, and the product obtained: s

20150017225 - Hemostatic pad assembly kit and method: The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue.... Agent:

20150017226 - Tolterodine-containing adhesive patch: The present invention provides a tolterodine-containing patch in which an adhesive layer is laminated on a backing, characterized in that the adhesive layer is obtainable by adding tolterodine to an adhesive base comprising a rubber adhesive, a tackifier resin, and a softener, wherein the tolterodine is present in the form... Agent:

20150017230 - Anti-epithelial cell adhesion molecule (epcam) antibodies and methods of use thereof: An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (EpCAM) comprising the amino acid sequence of SEQ ID NO: 1; (b) having a specific binding affinity to cancer... Agent: Academia Sinica

20150017233 - Arginine-based lipids for delivery of therapeutics: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs,... Agent:

20150017234 - Increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages: The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages. The allylamine active ingredient is prepared in an acidic environment; the acidic environment altering the physiochemical properties of the active ingredient resulting in the active ingredient having a positive... Agent:

20150017235 - Liposomes active in-vivo on neurodegenerative diseases: New liposomes are described, comprising: (i) phosphatidic acid and/or cardiolipin; (ii) apolipoprotein E (ApoE) or derivatives thereof. The so modified liposomes, administered systemically, obtain a dramatic in-vivo reduction of the amyloid plaque in the central nervous system, allowing an effective treatment of neurodegenerative diseases, in particular Alzheimer's disease.... Agent:

20150017229 - Method and system for synthesizing nanocarrier based long acting drug delivery system for insulin: The embodiments herein provide a long-acting injectable drug (insulin) delivery nano-carrier system and a method of synthesising the same. The insulin entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an... Agent: Kimia Zist Parsian Co

20150017228 - Method and system for synthesizing nanocarrier based long acting drug delivery system for morphine: The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of morphine and a method of synthesising the same. The morphine entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is... Agent: Kimia Zist Parsian Co

20150017227 - Methods and compositions for treating skin diseases and conditions: Disclosed are methods and compositions for treating skin diseases or conditions with a composition containing a lipid component as an active ingredient.... Agent:

20150017232 - Oligopeptidic compounds and uses thereof: wherein the oligopeptidic compound has 9-70 subunits and comprises at least one signal sequence, wherein the signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence and wherein in said compound a PCNA interacting motif is N-terminal to a signal sequence. Also disclosed are methods of... Agent:

20150017231 - Polyamine transport selective therapeutic agents with enhanced stability: Disclosed herein are di-substituted aryl polyamine compounds and methods of making and using the same. The di-substituted polyamine compounds act as PTS targeting agents, which selectively target the polyamine transport system (PTS) with high efficacy and have improved stability in the presence of amine oxidases.... Agent: University Of Central Florida Research Foundation, Inc.

20150017237 - Dosage form comprising lopinavir and ritonavir: The present invention relates to an oral dosage form comprising crystalline lopinavir and crystalline ritonavir. The invention further relates to methods of preparing said oral dosage forms containing the above pharmaceutical active agents.... Agent:

20150017236 - Pharmaceutical compositions of thyroid hormone: Provided herein are methods of stabilizing thyroid hormone, preventing a thyroid hormone from being oxidized, producing a formulation of thyroid hormone having a uniform potency, and reducing the exposure of a thyroid hormone to oxygen, light, moisture, or high temperature. Such methods comprise coating said thyroid hormone to provide a... Agent:

20150017238 - Methods and compositions for treating diabetes: Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.... Agent: Oramed, Ltd.

20150017239 - Method for treating intestinal diseases presenting at least one inflammatory component: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.... Agent: Cosmo Technologies Limited

20150017240 - Pharmaceutical compositions comprising a ph-dependent component and ph-raising agent: An oral pharmaceutical composition in unit dosage form comprising: (1) a first portion comprising: an active ingredient and a pH-dependent component, and (2) a second portion comprising a pH-raising agent is provided. Methods of administering the composition are also provided.... Agent:

20150017241 - Oral formulations of deferasirox: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.... Agent: Novartis Ag

20150017242 - Bilayer tablet of dronedarone: The present invention relates to multi component composition of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of multi component composition of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per... Agent:

20150017243 - Compositions and methods for enhancing brain function: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine... Agent:

20150017244 - Dry powder formulation of azole derivative for inhalation: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as... Agent: Galephar Pharmaceutical Research, Inc.

20150017245 - Methods of treating cancers with therapeutic nanoparticles: The present disclosure relates in part to methods of treating cholangiocarcinoma or tonsillar cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein nanoparticle composition comprises nanoparticles.... Agent:

20150017247 - Compositions for pulmonary delivery of long-acting b2 adrenergic receptor agonists and associated methods and systems: Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting β2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a... Agent:

20150017248 - Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation: Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of inflammatory and/or obstructive airways diseases.... Agent: Chiesi Farmaceutici S.p.a.

20150017246 - Novel crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof: The invention provides novel chemical entities based on sugar alcohols. These new chemical entities are biocompatible and biodegradable. The molecules can be made in a single and pure form. The molecular weights of these molecules range from small (<1000 Da) to large (1000-120,000 Da). The sugar alcohol-based molecules can have... Agent: Cellmosaic, Inc.

20150017249 - Sustained-release formulations of topiramate: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects... Agent: Supernus Pharmaceuticals, Inc.

20150017251 - Microparticles for use in immunogenic compositions: Immunogenic compositions are disclosed which comprise microparticles that comprise a biodegradable polymer, an immunological adjuvant and a tocol-family compound. Methods of making and using such microparticle compositions are also disclosed.... Agent: Novartis Ag

20150017250 - Tamper-resistant dosage form containing ethylene-vinyl acetate polymer: The invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene-vinyl acetate (EVA) polymer which provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.... Agent: Gr&#xdc Nenthal Gmbh

20150017253 - Composition for preventing or treating immune-related disease and oxidative-stress-related disease: The present invention relates to a composition for preventing or treating an immune-related disease, and, more specifically, relates to a composition for preventing or treating immune-related diseases or oxidative-stress-related diseases in which the toxicity of an arsenic compound is effectively suppressed while the immune function boosting effect thereof is nevertheless... Agent:

20150017252 - Supplement and medication cultivated plant delivery system: The embodiments disclose a supplement and medication cultivated plant delivery system including using a cultivation system for cultivating integrated enriched food products including fruits, produce and aquatic species and animal feeds, controlling and testing the cultivation system environment including an aqua cultivation media, incorporating a controlled feed system to raise... Agent:

20150017254 - Method for treatment of cardiovascular disorders: Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ECM based compositions include an ECM material derived from a... Agent:

20150017255 - Methods for treating cardiac conditions: Described herein are compositions and methods of treating a cardiac condition using modified placental tissue or an extract of a placental tissue, capable of recruiting stem cells or promoting healing in vivo and in vitro.... Agent:

20150017256 - Condensed iron (iii) phosphate: Method for producing condensed iron (III) phosphate, in which a) an aqueous solution containing Fe2+ ions is produced, in which oxidic iron (II), iron (III) or mixed iron (II, III) compounds selected from among hydroxides, oxides, oxide hydroxides, oxide hydrates, carbonates and hydroxide carbonates are introduced together with elementary iron... Agent:

20150017257 - Acidic electrolyzed water, manufacturing method therefor, and cleanser and disinfectant containing acidic electrolyzed water: To provide acidic electrolyzed water, a method for manufacturing acidic electrolyzed water, and a cleanser and a disinfectant containing acidic electrolyzed water which has disinfecting power for a long period of time, and which reduces the burden on living tissue. The acidic electrolyzed water has an effective chlorine concentration of... Agent: Molex Incorporated

20150017258 - Direct detection of disease biomarkers in clinical specimens using cationic nanoparticle-based assays & versatile and green methods for synthesis of anisotropic silver nanostructures: A gold nanoparticle-based assay for the detection of a target molecule, such as Hepatitis C Virus (HCV) RNA in serum samples, that uses positively charged gold nanoparticles (AuNPs) in solution based format. The assay has been tested on 74 serum clinical samples suspected of containing HCV RNA, with 48 and... Agent: American University Of Cairo (auc)

20150017259 - Integrin interaction inhibitors for the treatment of cancer: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA,... Agent:

20150017260 - Compositions of nutrition supplementation for nutritional deficiencies and method of use thereof: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective... Agent:

20150017261 - Methods of treating and preventing cancer by disrupting the binding of copper in the map kinase pathway: The present disclosure provides methods of treating and/or preventing cancer in a subject comprising administering to the subject a copper-reduced diet by itself or as a supplement along with a regular diet to create a copper-reduced melieu, maintain a reduced-copper melieu, or both, thereby treating and/or preventing the development of... Agent:

20150017263 - Fn14 antagonists and therapeutic uses thereof: The present disclosure is directed to methods of using fibroblast growth factor-inducible 14 (Fn14) antagonists to modulate activity at a TNF-like weak inducer of apoptosis (TWEAK) binding site on a cysteine-rich domain (CRD) of Fn14. The present disclosure also provides pharmaceutical compositions comprising synergistic combinations Fn14 antagonists and chemotherapeutic agents.... Agent:

20150017262 - Inhibition of dynamin related protein 1 to promote cell death: The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death by inhibiting Drp1. It is based, at least in part, on the discoveries that (i) Drp1 disruption-induced mitochondrial hyperfusion is functionally linked to the cell cycle regulation apparatus, so that Drp1 inhibition results in... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20150017264 - Procaspase 3 activation by combination therapy: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations... Agent: Theboard Of Trustees Of The University Of Illinois

20150017266 - Compositions and methods for relieving symptoms of rheumatoid arthritis and related illnesses: Compositions and methods for relieving symptoms of rheumatoid arthritis (RA) and related illnesses are disclosed. It appears that the primary cause of RA is a sensitivity or hypersensitivity to potassium and/or vitamin C, or too much potassium and/or vitamin C in the diet. The effects of potassium and vitamin C... Agent:

20150017265 - Methods of modifying myocardial infarction expansion: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from... Agent:

20150017267 - Treatment of inflammatory disorders in non-human mammals: The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.... Agent: The Regents Of The University Of California

20150017268 - Methods for improving milk letting down in milch animals: The invention concerns herbal compositions which improve lactation of farmed livestock comprising an effective amount of an extract and/or at least one bioactive fraction or powder from herbs such as Asparagus, Gossypium, Foeniculum, Lepidium, Chlorophytum, Ipomoea, Withania, Leptadenia and optionally dicalcium phosphate, chelated minerals and/or mineral mixture.... Agent:

20150017269 - New cosmetic use of an albizia julibrissin extract and corresponding topical composition: The present invention proposes an extract of Albizia Julibrissin for the cosmetic treatment of skin glycation. The extract is preferably obtained from flowers and/or seeds. Application to cosmetic formulations for treating cutaneous fatigue, in particular for improving the radiance of skin and eye contour (under eye bags and dark circles)... Agent: Sederma

20150017270 - Process for obtaining honey and/or flour of coffee from the pulp or husk and the mucilage of the coffee bean: The present invention relates to a method for using the by-products of coffee in the production of proteins, polyphenols, vitamins and minerals, through methods of concentrating and conserving the mucilage and the pulp (husk) in order to obtain industrially processed coffee honey and/or pulp meal (husk), which is/are suitable for... Agent:

  
  
Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus


######

RSS FEED for 20150122: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.83259 seconds

PATENT INFO